Akrivia, a pioneering neuroscience data company spun out from Oxford and the NHS, possesses one of world's largest and most valuable repositories of neuroscience data. Combining structured and unstructured data, Akrivia’s proprietary AI and NLP technologies allow for groundbreaking insights that drive pharmaceutical innovation. The company’s partnerships with industry leaders such as Johnson & Johnson underscore its credibility and impact.
With $12 million raised to date, Akrivia is now focusing on maximising the value of its assets while ensuring strong IP protection as it expands internationally.
With a growing footprint and increasing investor interest, Akrivia sought a structured, efficient way to map, value, and protect its critical assets:
Akrivia’s founders, the CEO and COO, engaged Intanify’s full Discover + Value + Risk capabilities, ensuring a thorough evaluation of its portfolio.
Discover – The platform mapped Akrivia’s key assets, consolidating structured and unstructured information into a holistic inventory of ~100 previously unrecognised assets.
Value – Using industry-standard methodologies, Intanify provided a detailed valuation of Akrivia’s AI, data assets, and proprietary tech.
Risk – A red flag analysis identified potential IP risks and provided actionable steps for mitigation.
Remarkably, the entire process required just two hours of engagement from Akrivia’s leadership team, with Intanify’s AI-driven platform automating the majority of the work.
Akrivia saw value from four key areas:
With this newfound clarity, Akrivia has now subscribed to Intanify as a long-term partner, ensuring its IP strategy remains robust and trade secrets are protected.